KannaLife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. KannaLife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of U.S. Patent 6,630,507, Cannabinoids as Antioxidants and Neuroprotectants (the 507 Patent). KannaLife is currently conducting research and development at the Bucks County Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE). HE is an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain. #6630507, 6630507